Eclampsia primary prevention: Difference between revisions
(Created page with "__NOTOC__ {{Eclampsia}} {{CMG}} Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing. ==Prevention== ...") |
|||
| Line 7: | Line 7: | ||
Detection and management of preeclampsia is critical to reduce the risk of eclampsia. Appropriate management of patients with preeclampsia generally involves the use of magnesium sulfate as an agent to prevent convulsions, and thus preventing eclampsia. | Detection and management of preeclampsia is critical to reduce the risk of eclampsia. Appropriate management of patients with preeclampsia generally involves the use of magnesium sulfate as an agent to prevent convulsions, and thus preventing eclampsia. | ||
Prevention of convulsion is usually done using [[magnesium sulfate]] (4-6 g loading dose in 100 ml iv fluid given over 15-20 minutes, then 2g per hour as a continuous infusion)<ref name=ACOG>{{cite journal |author=ACOG| title= Diagnosis and Management of Preeclampsia and Eclampsia |journal=ACOG Practice Bulletin # 33, 2002,}}</ref> Evidence for the use of magnesium sulfate came from the international MAGPIE study.<ref>{{cite journal |author=Frayling, Frayling |title=The Magpie Trial follow up study: outcome after discharge from hospital for women and children recruited to a trial comparing magnesium sulphate with placebo for pre-eclampsia [ISRCTN86938761] |journal= |volume=4 |issue=1 |pages=5 |year=2004 |pmid=15113445}}</ref> | Prevention of convulsion is usually done using [[magnesium sulfate]] (4-6 g loading dose in 100 ml iv fluid given over 15-20 minutes, then 2g per hour as a continuous infusion).<ref name=ACOG>{{cite journal |author=ACOG| title= Diagnosis and Management of Preeclampsia and Eclampsia |journal=ACOG Practice Bulletin # 33, 2002,}}</ref> Evidence for the use of magnesium sulfate came from the international MAGPIE study.<ref>{{cite journal |author=Frayling, Frayling |title=The Magpie Trial follow up study: outcome after discharge from hospital for women and children recruited to a trial comparing magnesium sulphate with placebo for pre-eclampsia [ISRCTN86938761] |journal= |volume=4 |issue=1 |pages=5 |year=2004 |pmid=15113445}}</ref> | ||
==References== | ==References== | ||
Revision as of 19:55, 11 February 2013
|
Eclampsia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Eclampsia primary prevention On the Web |
|
American Roentgen Ray Society Images of Eclampsia primary prevention |
|
Risk calculators and risk factors for Eclampsia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Prevention
Detection and management of preeclampsia is critical to reduce the risk of eclampsia. Appropriate management of patients with preeclampsia generally involves the use of magnesium sulfate as an agent to prevent convulsions, and thus preventing eclampsia.
Prevention of convulsion is usually done using magnesium sulfate (4-6 g loading dose in 100 ml iv fluid given over 15-20 minutes, then 2g per hour as a continuous infusion).[1] Evidence for the use of magnesium sulfate came from the international MAGPIE study.[2]
References
- ↑ ACOG. "Diagnosis and Management of Preeclampsia and Eclampsia". ACOG Practice Bulletin # 33, 2002,.
- ↑ Frayling, Frayling (2004). "The Magpie Trial follow up study: outcome after discharge from hospital for women and children recruited to a trial comparing magnesium sulphate with placebo for pre-eclampsia [ISRCTN86938761]". 4 (1): 5. PMID 15113445.